Metastatic Castrate Resistant Prostate Cancer (mCRPC) Clinical Trials
0 recruiting
Showing 1–4 of 4 trials
Recruiting
Phase 3
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Pfizer600 enrolled235 locationsNCT06551324
Recruiting
Phase 1
Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Metastatic Castrate Resistant Prostate Cancer (mCRPC)Prostate Cancer (CRPC)
ARTBIO Inc.80 enrolled3 locationsNCT07214961
Recruiting
Phase 1
Personalized vs. Fixed-Activity 177Lu-PSMA-617 Radiopharmaceutical Therapy (PRODIGY-2)
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Jean-Mathieu Beauregard60 enrolled1 locationNCT06943495
Recruiting
Kidney Function and Risk Factors in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Undergoing 177Lutetium-PSMA Radioligand Therapy: a Prospective Observational Study - KiRi-Trial
Metastatic Castrate Resistant Prostate Cancer (mCRPC)Kidney DiseaseRadiation Nephropathy
Hannah Schaefer100 enrolled1 locationNCT06720532